ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 969,94
-0,24%
Dow Jones
41 350,93
0,00%
DAX
22 563,35
-0,46%
Brent Oil
70,115
-0,81%
Bitcoin
82 567,12
-1,32%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Lexeo Therapeutics Inc (LXEO)

  7. Lexeo Therapeutics Inc (LXEO) Actualités

LXEO

Lexeo Therapeutics (LXEO)

Lexeo Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:LXEO
DateHeureSourceTitreSymboleSociété
21/02/202523h10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LXEOLexeo Therapeutics Inc
19/02/202522h25Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:LXEOLexeo Therapeutics Inc
12/02/202515h35Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:LXEOLexeo Therapeutics Inc
04/02/202521h45Edgar (US Regulatory)Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:LXEOLexeo Therapeutics Inc
13/01/202513h35Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LXEOLexeo Therapeutics Inc
07/01/202513h30GlobeNewswire Inc.Lexeo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:LXEOLexeo Therapeutics Inc
27/12/202420h59Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:LXEOLexeo Therapeutics Inc
20/12/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:LXEOLexeo Therapeutics Inc
19/12/202413h00GlobeNewswire Inc.Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial OfficerNASDAQ:LXEOLexeo Therapeutics Inc
13/12/202414h19Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:LXEOLexeo Therapeutics Inc
02/12/202423h04Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:LXEOLexeo Therapeutics Inc
13/11/202413h35Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:LXEOLexeo Therapeutics Inc
13/11/202413h33Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LXEOLexeo Therapeutics Inc
13/11/202413h30GlobeNewswire Inc.Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial ResultsNASDAQ:LXEOLexeo Therapeutics Inc
30/10/202411h14GlobeNewswire Inc.Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer’s Disease, at the Clinical Trials on Alzheimer’s Disease (CTAD) ConferenceNASDAQ:LXEOLexeo Therapeutics Inc
22/10/202413h30GlobeNewswire Inc.Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 ConferenceNASDAQ:LXEOLexeo Therapeutics Inc
05/09/202413h30GlobeNewswire Inc.Lexeo Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:LXEOLexeo Therapeutics Inc
12/08/202413h00GlobeNewswire Inc.Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational HighlightsNASDAQ:LXEOLexeo Therapeutics Inc
15/07/202412h00GlobeNewswire Inc.Lexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia CardiomyopathyNASDAQ:LXEOLexeo Therapeutics Inc
11/07/202414h00GlobeNewswire Inc.Lexeo Therapeutics Announces Investor Webcast to Report Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy on Monday, July 15, 2024NASDAQ:LXEOLexeo Therapeutics Inc
08/07/202413h00GlobeNewswire Inc.Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of DirectorsNASDAQ:LXEOLexeo Therapeutics Inc
09/05/202413h00GlobeNewswire Inc.Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational HighlightsNASDAQ:LXEOLexeo Therapeutics Inc
22/04/202413h30GlobeNewswire Inc.Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia CardiomyopathyNASDAQ:LXEOLexeo Therapeutics Inc
16/04/202413h30GlobeNewswire Inc.Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia CardiomyopathyNASDAQ:LXEOLexeo Therapeutics Inc
13/03/202421h22GlobeNewswire Inc.Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity FinancingNASDAQ:LXEOLexeo Therapeutics Inc
11/03/202421h09Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:LXEOLexeo Therapeutics Inc
11/03/202414h29Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:LXEOLexeo Therapeutics Inc
11/03/202412h42GlobeNewswire Inc.Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational HighlightsNASDAQ:LXEOLexeo Therapeutics Inc
11/03/202412h30GlobeNewswire Inc.Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity FinancingNASDAQ:LXEOLexeo Therapeutics Inc
05/02/202413h00GlobeNewswire Inc.Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive AppointmentsNASDAQ:LXEOLexeo Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:LXEO

Dernières Valeurs Consultées

LSE
3GDE
3x Gold Mine
BIT
P1M388
BNP Paribas Issuance
BIT
UC4VDK
Unicredit Bank
BIT
UC2320
Unicredit Bank
BIT
F34731
Vontobel Financial Produ...
BIT
P1OL35
BNP Paribas Issuance
BIT
UC5F4Y
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés

Supprimer les publicités

Inscrivez-vous pour une expérience sans publicité

Aucune publicité

Essayez maintenant

Conserver les annonces